Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in atypical teratoid/rhabdoid tumorsDennis S. Metselaar, Esther Hulleman, Marjolein Breur et al.|Cell Reports Medicine|2024Cited by 8
MDB-68. DISCOVERING DRUG SENSITIVITIES IN MEDULLOBLASTOMA USING PATIENT- AND PDX-DERIVED TUMOROIDSChris Meulenbroeks, Marcel Kool, Phylicia Stathi et al.|Neuro-Oncology|2024Cited by 2
BIOM-51. MOLECULAR SUBTYPES, CLINICAL CHARACTERISTICS, AND THERAPEUTIC IMPLICATIONS FOR CNS TUMORS WITH<i>BCOR/BCORL1</i> FUSION/INTERNAL TANDEM DUPLICATIONJohannes Gojo, Marcel Kool, Aniello Federico et al.|Neuro-Oncology|2024Cited by 0
P10.27.B PRECLINICAL MODELLING AND DRUG SENSITIVITY DISCOVERY USING PATIENT- AND PDX-DERIVED TUMOROIDS OF HIGH RISK MEDULLOBLASTOMAChris Meulenbroeks, M Kool, Phylicia Stathi et al.|Neuro-Oncology|2025Cited by 0